Cargando…

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Funakoshi, Yusuke, Hata, Nobuhiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Mizoguchi, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766528/ https://www.ncbi.nlm.nih.gov/pubmed/33339404 http://dx.doi.org/10.3390/ph13120470

Ejemplares similares

ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application
por: Funakoshi, Yusuke, et al.
Publicado: (2020)

Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma)
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT
por: Hata, Nobuhiro, et al.
Publicado: (2019)

MPC-06 Cutting-edge of Cancer Genomic Medicine for brain tumors
por: Mizoguchi, Masahiro, et al.
Publicado: (2020)

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma
por: Takigawa, Kosuke, et al.
Publicado: (2021)

Supramaximal Resection Can Prolong the Survival of Patients with Cortical Glioblastoma: A Volumetric Study
por: OTSUJI, Ryosuke, et al.
Publicado: (2023)

Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid
por: Fujioka, Yutaka, et al.
Publicado: (2021)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Mesenchymal glioblastoma-induced mature de-novo vessel formation of vascular endothelial cells in a microfluidic device
por: Amemiya, Takeo, et al.
Publicado: (2021)

Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status
por: Hata, Nobuhiro, et al.
Publicado: (2017)

Liquid biopsy with multiplex ligation-dependent probe amplification targeting cell-free tumor DNA in cerebrospinal fluid from patients with adult diffuse glioma
por: Otsuji, Ryosuke, et al.
Publicado: (2022)

CD206 Expression in Induced Microglia-Like Cells From Peripheral Blood as a Surrogate Biomarker for the Specific Immune Microenvironment of Neurosurgical Diseases Including Glioma
por: Tanaka, Shunya, et al.
Publicado: (2021)

Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors
por: Sangatsuda, Yuhei, et al.
Publicado: (2020)

TBIO-08. BASE-RESOLUTION METHYLOMES OF GLIOMAS BEARING HISTONE H3.3 MUTATIONS REVEAL A G34 MUTANT-SPECIFIC SIGNATURE SHARED WITH BONE TUMORS
por: Sangatsuda, Yuhei, et al.
Publicado: (2020)

IM-03 CD206 expression in peripheral blood-derived induced-microglia-like cells as a surrogate biomarker for the specific immune microenvironment of glioma
por: Hata, Nobuhiro, et al.
Publicado: (2020)

A case of metastatic brain tumor in the perfusion territory of superficial temporal artery-middle cerebral artery anastomosis
por: Fujioka, Yutaka, et al.
Publicado: (2015)

Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor)
por: YOSHIMOTO, Koji, et al.
Publicado: (2016)

Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data
por: Hatae, Ryusuke, et al.
Publicado: (2016)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

Giant cranial angiolipoma with arteriovenous fistula: A case report
por: Hatae, Ryusuke, et al.
Publicado: (2022)

Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade
por: Hata, Nobuhiro, et al.
Publicado: (2016)

Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR
por: Yoshimoto, Koji, et al.
Publicado: (2011)

Papillary craniopharyngioma coexisting with an intratumoral abscess in a pediatric patient: A case report and review of the literature
por: Takagi, Katsuhiro, et al.
Publicado: (2021)

Gamma distribution model of diffusion MRI for the differentiation of primary central nerve system lymphomas and glioblastomas
por: Togao, Osamu, et al.
Publicado: (2020)

Clinical implications of microRNAs in human glioblastoma
por: Mizoguchi, Masahiro, et al.
Publicado: (2013)

HGG-24. HIGH-GRADE GLIOMA WITH A NOVEL FUSION GENE OF VCL-ALK
por: Yamamoto, Shunsuke, et al.
Publicado: (2020)

Nonconvulsive status epilepticus associated with Alzheimer’s disease mimicking symptomatic focal epilepsy following the resection of a frontal parasagittal meningioma
por: Abe, Keisuke, et al.
Publicado: (2020)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Screening of promising chemotherapeutic candidates from plants extracts
por: Kinjo, Junei, et al.
Publicado: (2016)

Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study
por: Kikuchi, Kazufumi, et al.
Publicado: (2022)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
por: Wagle, Naveed, et al.
Publicado: (2010)

ANGI-2 Identification and functions of CD44 as a predictor for bevacizumab-resistant glioblastoma to optimally treat the tumor with bevacizumab
por: Inoue, Akihiro, et al.
Publicado: (2021)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma
por: Annovazzi, Laura, et al.
Publicado: (2017)

Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
por: Adilijiang, Alimu, et al.
Publicado: (2019)

Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab
por: Taniguchi, Hirokazu, et al.
Publicado: (2013)

Histopathological investigation of glioblastomas resected under bevacizumab treatment
por: Tamura, Ryota, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6po90884cbmqtlb7fki3mco46t